BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borgenvik A, Čančer M, Hutter S, Swartling FJ. Targeting MYCN in Molecularly Defined Malignant Brain Tumors. Front Oncol 2020;10:626751. [PMID: 33585252 DOI: 10.3389/fonc.2020.626751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Whitfield JR, Soucek L. The long journey to bring a Myc inhibitor to the clinic. J Cell Biol 2021;220:e202103090. [PMID: 34160558 DOI: 10.1083/jcb.202103090] [Reference Citation Analysis]
2 Gargini R, Segura-collar B, Garranzo-asensio M, Hortigüela R, Iglesias-hernández P, Lobato-alonso D, Moreno-raja M, Esteban-martin S, Sepúlveda-sánchez JM, Nevola L, Sánchez-gómez P. IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas. Neurotherapeutics. [DOI: 10.1007/s13311-021-01176-6] [Reference Citation Analysis]
3 Morimoto Y, Tokumitsu A, Sone T, Hirota Y, Tamura R, Sakamoto A, Nakajima K, Toda M, Kawakami Y, Okano H, Ohta S. TPT1 Supports Proliferation of Neural Stem/Progenitor Cells and Brain Tumor Initiating Cells Regulated by Macrophage Migration Inhibitory Factor (MIF). Neurochem Res 2022. [PMID: 35622214 DOI: 10.1007/s11064-022-03629-6] [Reference Citation Analysis]
4 Braoudaki M, Hatziagapiou K, Zaravinos A, Lambrou GI. MYCN in Neuroblastoma: "Old Wine into New Wineskins". Diseases 2021;9:78. [PMID: 34842635 DOI: 10.3390/diseases9040078] [Reference Citation Analysis]
5 Shatara M, Schieffer KM, Klawinski D, Thomas DL, Pierson CR, Sribnick EA, Jones J, Rodriguez DP, Deeg C, Hamelberg E, LaHaye S, Miller KE, Fitch J, Kelly B, Leraas K, Pfau R, White P, Magrini V, Wilson RK, Mardis ER, Abdelbaki MS, Finlay JL, Boué DR, Cottrell CE, Ghasemi DR, Pajtler KW, Osorio DS. Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas. Acta Neuropathol Commun 2021;9:192. [PMID: 34895332 DOI: 10.1186/s40478-021-01296-2] [Reference Citation Analysis]
6 Moreno DA, da Silva LS, Zanon MF, Bonatelli M, de Paula FE, de Medeiros Matsushita M, Teixeira GR, Santana IVV, Saggioro F, Neder L, Stavale JN, Malheiros SMF, Lima M, Hajj GNM, Garcia-Rivello H, Christiansen S, Nunes S, da Costa MJG, Soares MJ, Pinheiro J, Junior CA, Mançano BM, Reis RM. Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study. J Neurooncol 2022. [PMID: 35166989 DOI: 10.1007/s11060-022-03965-1] [Reference Citation Analysis]